Suppr超能文献

托吡酯作为一种情绪稳定剂。

Topiramate as a mood stabilizer.

作者信息

Letmaier M, Schreinzer D, Wolf R, Kasper S

机构信息

Department of General Psychiatry, University of Vienna, Austria.

出版信息

Int Clin Psychopharmacol. 2001 Sep;16(5):295-8. doi: 10.1097/00004850-200109000-00008.

Abstract

Topiramate is a novel anticonvulsant agent with a broad spectrum mechanism of action, and recent clinical reports indicate that it may have mood stabilizing properties in bipolar disorder. Therefore, we treated a 41-year-old woman who had 12 previous hospitalizations for acute mania during a 10-year history of bipolar I disorder with this compound. Since 1991, the patient had been treated with carbamazepine, valproate and lamotrigine with limited success. At the beginning of a new manic episode, topiramate was started in the outpatient clinic. Eight weeks after initiation of treatment, the patient was hospitalized. This inpatient treatment lasted less than 3 weeks. Subsequently, the patient has not been hospitalized again. Topiramate was well tolerated. Even though, during subsequent topiramate treatment, a serious life event (suicide attempt of brother) induced re-occurence of the patient's psychopathology, which did not require hospitalization. Fortunately, inpatient treatment was not necessary due to an increase of topiramate dosage and addition of risperidone and clonazepam. The patient, now on 200 mg/day, is mostly asymptomatic and has functioned well for over 17 months, in contrast to 13 hospitalizations during the previous 10 years.

摘要

托吡酯是一种新型抗惊厥药物,作用机制具有广谱性,近期临床报告表明它在双相情感障碍中可能具有稳定情绪的特性。因此,我们用这种化合物治疗了一名41岁的女性,她在10年的I型双相情感障碍病史中因急性躁狂症曾12次住院。自1991年以来,该患者先后接受过卡马西平、丙戊酸盐和拉莫三嗪治疗,但效果有限。在一次新的躁狂发作开始时,在门诊开始使用托吡酯治疗。治疗开始8周后,患者住院。这次住院治疗持续不到3周。随后,患者未再次住院。托吡酯耐受性良好。尽管在随后的托吡酯治疗期间,一次严重的生活事件(其兄弟自杀未遂)导致患者精神病理学复发,但未需要住院治疗。幸运的是,由于增加了托吡酯剂量并加用了利培酮和氯硝西泮,无需住院治疗。该患者目前每天服用200毫克托吡酯,大多无症状,在过去17个月中功能良好,而此前10年曾住院13次。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验